Natera, Inc. (NASDAQ:NTRA) Receives $86.40 Consensus Price Target from Brokerages

Shares of Natera, Inc. (NASDAQ:NTRA) have earned a consensus recommendation of “Buy” from the fourteen brokerages that are covering the stock, MarketBeat Ratings reports. Fourteen equities research analysts have rated the stock with a buy rating. The average 12-month target price among analysts that have covered the stock in the last year is $86.40.

A number of analysts have recently weighed in on the stock. BTIG Research raised their price target on shares of Natera from $75.00 to $85.00 and gave the stock a “buy” rating in a research report on Friday, December 29th. Raymond James cut Natera from a “strong-buy” rating to an “outperform” rating and upped their price objective for the company from $68.00 to $85.00 in a research note on Tuesday, February 20th. Craig Hallum assumed coverage on Natera in a research report on Monday, April 8th. They issued a “buy” rating and a $117.00 target price for the company. Piper Sandler upped their price target on Natera from $70.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, March 6th. Finally, Canaccord Genuity Group boosted their target price on shares of Natera from $87.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, February 29th.

Natera Stock Performance

Natera stock opened at $91.28 on Tuesday. The stock has a fifty day moving average of $87.29 and a two-hundred day moving average of $67.00. Natera has a fifty-two week low of $36.90 and a fifty-two week high of $98.82. The company has a market capitalization of $11.02 billion, a price-to-earnings ratio of -24.08 and a beta of 1.37. The company has a debt-to-equity ratio of 0.37, a quick ratio of 3.96 and a current ratio of 4.10.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.09. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. The company had revenue of $311.11 million for the quarter, compared to the consensus estimate of $300.38 million. On average, analysts anticipate that Natera will post -2.35 EPS for the current fiscal year.

Insider Transactions at Natera

In related news, insider John Fesko sold 2,358 shares of the company’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $65.09, for a total transaction of $153,482.22. Following the transaction, the insider now directly owns 108,494 shares of the company’s stock, valued at $7,061,874.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider John Fesko sold 2,358 shares of the firm’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $65.09, for a total transaction of $153,482.22. Following the completion of the sale, the insider now directly owns 108,494 shares in the company, valued at $7,061,874.46. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Michael Burkes Brophy sold 3,235 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $65.09, for a total transaction of $210,566.15. Following the completion of the transaction, the chief financial officer now owns 92,927 shares in the company, valued at approximately $6,048,618.43. The disclosure for this sale can be found here. Insiders sold a total of 453,644 shares of company stock valued at $36,594,940 over the last quarter. Company insiders own 9.42% of the company’s stock.

Hedge Funds Weigh In On Natera

Institutional investors have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC increased its holdings in shares of Natera by 28.6% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 720,160 shares of the medical research company’s stock valued at $45,111,000 after acquiring an additional 159,993 shares during the last quarter. Cerity Partners LLC lifted its position in shares of Natera by 1,043.3% in the 4th quarter. Cerity Partners LLC now owns 90,423 shares of the medical research company’s stock worth $5,664,000 after acquiring an additional 82,514 shares during the period. WCM Investment Management LLC increased its position in shares of Natera by 101.2% during the fourth quarter. WCM Investment Management LLC now owns 145,996 shares of the medical research company’s stock valued at $9,058,000 after purchasing an additional 73,419 shares during the period. Aigen Investment Management LP acquired a new position in shares of Natera in the third quarter valued at $223,000. Finally, Sei Investments Co. lifted its position in Natera by 33.4% in the third quarter. Sei Investments Co. now owns 374,004 shares of the medical research company’s stock worth $16,550,000 after purchasing an additional 93,556 shares during the period. 99.90% of the stock is currently owned by institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.